Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

>The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

>SHANGHAI, China, March 26, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line […]